FMTVDM; B.E.S.T.©℗ Imaging Theranostically Used to Guide Treatment Response in a Woman with Recalcitrant Breast Cancer

Richard M Fleming*¹, Matthew R Fleming BS¹, Tapan K Chaudhuri², William C Dooley³ and Andrew McKusick^1,4

Received: November 18, 2018;   Published: November 28, 2018

DOI: 10.26717/BJSTR.2018.11.002111

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Until quite recently, diagnostic imaging has relied upon “qualitative” imaging methods limited by “inattention blindness”, reader expectation bias and the ability to define disease as either present or absent. The first marker that you are using a “qualitative” test is a discussion of sensitivity, the ability to find disease when present and specificity, the ability to exclude disease when absent [1-9]. This yes/no approach to medicine reflects the limitations qualitatively imposed upon us despite the understanding that tissues don’t simply exist in either a “normal” or “diseased” state but rather a transition occurs as the genetic and environmental factors influencing tissues results in changes; transitional changes, which can now be fully appreciated and measured [1-9]. The quantitative ability to measure Breast Health, using Breast Enhanced Scintigraphy Test [FMTVDM©℗; B.E.S.T.©℗] Imaging by measuring regional blood flow differences (RBFDs) and tissue metabolism [1-9] makes it possible to differentiate several changes in tissue type; recognizing a “Health-Spectrum” defined by Figure 1.

Keywords : FMTVDM©℗; B.E.S.T. Imaging©℗; Breast Cancer; Breast Inflammation; Theranostics; Quantification; AI

Abbreviations : BEST: Brest Enhanced Scintigraphy Test; RBFD: Regional Blood Flow Differences